Overview
Elutia Q3 revenue missed analyst expectations
Company completed $88 mln sale of BioEnvelope business to Boston Scientific
Gross margin improved to 55.8% from 48.9% in Q3 2024
Outlook
Elutia anticipates FDA clearance for NXT-41x base matrix in 2H26
Company expects drug-eluting NXT-41x version clearance in 1H27
Result Drivers
BIOENVELOPE SALE - Sale of BioEnvelope business to Boston Scientific for $88 mln used to eliminate debt and fund NXT-41x development
NXT-41X DEVELOPMENT - Advancing NXT-41x to address infections in plastic and reconstructive surgery, targeting a $1.5 bln market
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | Miss | $3.32 mln | $6.65 mln (2 Analysts) |
Q3 Net Income | -$3.87 mln | ||
Q3 Gross Profit | $1.85 mln | ||
Q3 Income From Operations | -$5.21 mln | ||
Q3 Operating Expenses | $7.06 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Elutia Inc is $4.00, about 76% above its November 5 closing price of $0.96
Press Release: ID:nGNX4njjLm
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)